Analyst Research

Report Title Price
Provider: Wright Reports
Provider: Stock Traders Daily
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biomarin Pharmaceutical Inc Reaffirms FY 2013 Guidance

Thursday, 25 Apr 2013 04:03pm EDT 

Biomarin Pharmaceutical Inc announced that for fiscal 2013, it expects total revenue of $530 to $555 million, GAAP net loss of $(195) to $(170) million and non-GAAP adjusted EBITDA (loss) $(75) to $(50) million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $550 million for fiscal 2013. 

Company Quote

29 Jan 2015